David Charles Lubner

CIK 1572000 · Executive VP and CFO · last filed 2026-08-07

David Charles Lubner is an Executive VP and CFO who has filed 57 SEC Form 4 insider transactions across 11 companies since 2013. The most recent filing, for BRVE, was dated Aug 7, 2026. Across all open-market trades the lifetime net is −$1.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.1M across reported positions. 1 Form 144 notice of planned sales is also on file; the latest, for ACLX on Jan 20, 2026, lists the filer as a director.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$1.05M
Companies
11
Total Filings
57
Lifetime Open-Market Net
-$1.78M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

TTPH price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
C/O TETRAPHASE PHARMACEUTICALS, INC.
480 ARSENAL STREET, SUITE 110
WATERTOWN, MA 02472
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count in each company: direct shares plus every indirect holder (trusts, LLCs, partnerships, family members) on the latest Form 4 that lists them. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
BRVE Director 55,555 $18.93 $1.05M $1000.0K 1 2026-08-07
DYN Director 0 $16.04 $0 $0 9 2026-06-09
CRESCENT BIOPHARMA, INC. (GLYC) Delisted Director — $15.70 — $0 2 2026-06-03
Arcellx, Inc. (ACLX) Delisted Director 0 $115.07 $0 -$450.0K 7 2026-04-28
CARGO Therapeutics, Inc. (CRGX) Delisted Director — $4.47 — $0 4 2025-08-19
VOR Director — $18.27 — $0 5 2025-05-23
POINT Biopharma Global Inc. (PNT) Delisted Director 0 $12.50 $0 $24.7K 5 2023-12-27
Disc Medicine, Inc. (GMTX) Delisted Director — $13.50 — $0 5 2022-03-09
Ra Pharmaceuticals, Inc. (RARX) Delisted Executive VP and CFO 0 — — $0 5 2020-04-03
NITE Director 0 $34.77 $0 $0 2 2019-06-07
TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted SVP and CFO 3,938 — — -$2.35M 11 2015-08-17

Recent Filings

57 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144, so not all of them end in a sale. Under each notice: the role the filer ticked on it, and whether a sale followed (a Form 4 sale within 30 days, or a sale listed on a later notice).
Filed Symbol Action Net Shares Net $ Link
2026-08-07 BRVE Mixed +55,555 $1000.0K EDGAR
2026-06-09 DYN Grant (A) — $0 EDGAR
2026-06-03 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Grant (A) — $0 EDGAR
2026-04-28 Arcellx, Inc. (ACLX) Delisted Mixed −21,659 $0 EDGAR
2026-04-28 DYN Gift (G) −53,625 $0 EDGAR
2026-01-20 Arcellx, Inc. (ACLX) Delisted Notice (144)
Director · Planned Jan 20, 2026 · 10b5-1 plan
Sold: Form 4 filed Jan 20, 2026
−15,000 -$1.03M EDGAR
2026-01-20 Arcellx, Inc. (ACLX) Delisted Mixed10b5-1
Plan adopted Sep 29, 2025
— -$412.3K EDGAR
2025-08-19 CARGO Therapeutics, Inc. (CRGX) Delisted Disp (D) — $0 EDGAR
2025-06-23 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Grant (A) — $0 EDGAR
2025-06-20 CARGO Therapeutics, Inc. (CRGX) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 57
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).